accountCOPD in November 2009, boosting the Swiss drugmaker's ambitions in respiratory medicine, a field currently dominated by GlaxoSmithKline (GSK.L The U.S. Food and Drug Administration is due to rule whether it will back the drug in July. [ID:nLDE72M06Z]...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Novartis Onbrez plus rival boosts lung function
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account